P. This

发表

A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk.

G. Leclercq, P. de Cremoux, Y. Jacquot, 2011, Maturitas.

Phytoestrogens after breast cancer.

H. Magdelenat, A. Fourquet, K. Clough, 2001, Endocrine-related cancer.

Hormone Replacement Therapy after Prophylactic Adnexectomy

D. Stoppa-Lyonnet, B. Sigal-Zafrani, S. Dolbeault, 2005, Hereditary cancer in clinical practice.

[Hormone replacement therapy after endometrial cancer: an opportunity to supervise!].

P. This, 2011, Gynecologie, obstetrique & fertilite.

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

X. Sastre, B. Asselain, D. Stoppa-Lyonnet, 2007 .

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome

B. Asselain, D. Stoppa-Lyonnet, A. Tardivon, 2012, Familial Cancer.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2011, Familial Cancer.

Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes.

G. Leclercq, P. de Cremoux, Y. Jacquot, 2011, Maturitas.

Controversies concerning the use of phytoestrogens in menopause management: bioavailability and metabolism.

G. Leclercq, P. de Cremoux, Y. Jacquot, 2010, Maturitas.

Prevalence and associated factors of sexual problems after early‐stage breast cancer treatment: results of a French exploratory survey

B. Asselain, C. Flahault, L. Copel, 2011, Psycho-oncology.

[Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004].

L. Mauriac, A. Tardivon, B. Sigal-Zafrani, 2005, Bulletin du cancer.

Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women

O. Chevallier, P. This, G. Durand, 2002, Climacteric : the journal of the International Menopause Society.

Cancer and fecundity issues mandate a multidisciplinary approach.

C. Chapron, D. de Ziegler, C. Decanter, 2010, Fertility and sterility.

[Phytoestrogens in the contraindication of hormone replacement therapy. The problem of breast cancer].

H. Magdelenat, A. Fourquet, K. Clough, 2000, Gynecologie, obstetrique & fertilite.

[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies].

B. Asselain, D. Stoppa-Lyonnet, C. Houdayer, 2009, Bulletin de l'Academie nationale de medecine.

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Bernard Asselain, Dominique Stoppa-Lyonnet, B. Asselain, 2010, Breast Cancer Research and Treatment.

L'induction de l'ovulation

P. This, 1994 .

[Contraception's choice: women's opinion, satisfaction and profile. Results of a French national survey of a representative sample of 5963 women].

P. Panel, C. Chis, P. This, 2014, Gynecologie, obstetrique & fertilite.

Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome

B. Asselain, D. Stoppa-Lyonnet, A. Tardivon, 2012, Familial Cancer.

Phytoestrogens and adjuvant endocrine treatment of breast cancer.

H. Magdelenat, P. This, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in a randomized control trial? Comments concerning MA 17.

B. Asselain, A. Brédart, S. Dolbeault, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].

D. Stoppa-Lyonnet, T. Maudelonde, P. Pujol, 2004, Bulletin du cancer.

Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial.

J. Lemonnier, P. Pujol, J. Fricker, 2020 .

[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].

F. Reyal, D. Stoppa-Lyonnet, C. Noguès, 2016, Bulletin du cancer.

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial

J. Lemonnier, P. Pujol, J. Fricker, 2012, Familial Cancer.

Prevalence and associated factors of sexual problems after early‐stage breast cancer treatment: results of a French exploratory survey

B. Asselain, C. Flahault, L. Copel, 2011, Psycho-oncology.

[Breast cancer and fertility: critical review, considerations and perspectives].

P. This, 2008, Bulletin du cancer.